Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.48 |
| ▸ | CCR8 | P51685 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18774829 | 0.80 | CCR1 (0.65) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL12853125 | 0.80 | LMNA (0.61) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL12853122 | 0.80 | LMNA (0.61) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL170352 | 0.80 | LMNA (0.61) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL7555958 | 0.80 | LMNA (0.56) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL28822835 | 0.80 | LMNA (0.56) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL16541136 | 0.79 | CDK5 (0.41) | LMNAKDM4EMAPTHTTHSP90AA1 | |
| SCHEMBL29871258 | 0.79 | ALDH1A1 (0.58) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| Phenanthroline SCHEMBL10380787 | 0.79 | CCR1 (0.62) | LMNAKDM4ESMN1; SMN2TDP1MAPT | |
| SCHEMBL21390912 | 0.79 | ALDH1A1 (0.58) | LMNAKDM4ESMN1; SMN2TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307514-A | Organic electroluminescent compound and organic electroluminescent device comprising the same | 罗门哈斯电子材料韩国有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024120442-A1 | PAK4 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CONVERGEN (SUZHOU) PHARMACEUTICAL CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024104384-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NUCMITO PHARMACEUTICALS CO. LTD. (CN) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024094064-A1 | PYRIMIDINYLAMINOBENZENES FOR TREATING LUNG CANCER WITH DISTANT METASTASIS | SUZHOU PUHE BIOPHARMA CO., LTD (CN) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094125-A1 | LIPID COMPOUNDS, LIPID NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024061157-A1 | CARBOHYDRATE-OLIGONUCLEOTIDE CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2024-03-28 | — | — | WO | disclosed |
| EP-4337628-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Nucmito Pharmaceuticals Company Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| EP-4330256-A1 | PYRIMIDINYLAMINOBENZENES FOR LUNG CANCER TREATMENT | Suzhou Puhe Biopharma Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024037503-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO., LTD. (CN) | 2024-02-22 | — | — | WO | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | LMNA 2842/4885KDM4E 3631/4885SMN1; SMN2 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.